Liverpool HEP Interactions

Coadministration may decrease velpatasvir concentrations. Coadministration of Epclusa with efavirenz-containing regimens is not recommended. Coadministration of efavirenz (600 mg once daily with emtricitabine and tenofovir-DF) and sofosbuvir/velpatasvir (400/100 mg once daily) increased sofosbuvir Cmax by 38% but decreased AUC by 3%; Cmax and AUC of GS-331007 decreased by 14% and 10%, but Cmin increased by 1%; velpatasvir Cmax, AUC and Cmin decreased by 47%, 53% and 57%, respectively (n=14). Efavirenz Cmax, AUC and Cmin decreased by 19%, 15% and 10%, respectively (n=15).

Epclusa Prescribing Information, Gilead Science Inc., June 2021.

Coadministration of sofosbuvir/velpatasvir (400/100 mg, once daily) with efavirenz/emtricitabine/tenofovir-DF (600/200/300 mg, once daily) was studied in 24 healthy volunteers. Sofosbuvir AUC decreased by 3% and Cmax increased by 38%. GS-331007 AUC and Cmax decreased by 10% and 14%, while Ctau increased by 1%. Velpatasvir AUC, Cmax, and Ctau decreased by 53%, 47%, and 57% respectively. Coadministration is not recommended due to the reduction in velpatasvir exposure.

Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers. Mogalian E, Stamm L M, Osinusi A et al. Clin Infect Dis, 2018; 67(6): 934-940.